Fernando Martinez to Antibodies, Monoclonal
This is a "connection" page, showing publications Fernando Martinez has written about Antibodies, Monoclonal.
Connection Strength
0.157
-
Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, Mack M, Dasgupta B, Nnane IP, Flavin SK, Barnathan ES. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015 Dec; 46(6):1740-50.
Score: 0.091
-
Raghu G, Mouded M, Chambers DC, Martinez FJ, Richeldi L, Lancaster LH, Hamblin MJ, Gibson KF, Rosas IO, Prasse A, Zhao G, Serenko M, Novikov N, McCurley A, Bansal P, Stebbins C, Arefayene M, Ibebunjo S, Violette SM, Gallagher D, Behr J. A Phase IIb Randomized Clinical Study of an Anti-av?6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 11 01; 206(9):1128-1139.
Score: 0.037
-
Skj?t-Arkil H, Clausen RE, Nguyen QH, Wang Y, Zheng Q, Martinez FJ, Hogaboam CM, Han M, Klickstein LB, Larsen MR, Nawrocki A, Leeming DJ, Karsdal MA. Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation. BMC Pulm Med. 2012 Jul 20; 12:34.
Score: 0.018
-
Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP. Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother. 2004 Aug; 5(8):1671-86.
Score: 0.010